NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Phase 3

Suspended

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Echocardiography Test
Other: Fludeoxyglucose F-18
Radiation: Intensity-Modulated Radiation Therapy
Biological: Nivolumab
Other: Patient Observation
Procedure: Positron Emission Tomography

First Posted Date: 2019-01-22

Last Posted Date: 2025-05-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 636

Registration Number: NCT03811015

Locations: 🇺🇸
Thomas Hospital, Fairhope, Alabama, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 727 locations

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3

Active, not recruiting

Conditions: Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Limited Stage Lung Small Cell Carcinoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Biospecimen Collection
Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Radiation: Intensity-Modulated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-01-22

Last Posted Date: 2025-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 544

Registration Number: NCT03811002

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 541 locations

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Phase 1

Active, not recruiting

Conditions: Hairy Cell Leukemia

Interventions: Drug: Moxetumomab Pasudotox-tdfk
Biological: Rituximab
Biological: Ruxience
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Famotidine
Drug: Aspirin

First Posted Date: 2019-01-16

Last Posted Date: 2024-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03805932

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Men at High Genetic Risk for Prostate Cancer

Recruiting

Conditions: Prostatic Neoplasms

First Posted Date: 2019-01-16

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT03805919

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Phase 1

Withdrawn

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Prognostic Stage IV Breast Cancer AJCC v8

Interventions: Drug: Copanlisib
Drug: Fulvestrant

First Posted Date: 2019-01-15

Last Posted Date: 2023-09-25

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03803761

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

and more 4 locations

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1

Active, not recruiting

Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma
Nasopharyngeal Squamous Cell Carcinoma
Sinonasal Squamous Cell Carcinoma

Interventions: Procedure: Biopsy Procedure
Drug: Birinapant
Procedure: Computed Tomography
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2019-01-15

Last Posted Date: 2025-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT03803774

Locations: 🇺🇸
HaysMed, Hays, Kansas, United States
🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
Mercy Hospital Pittsburg, Pittsburg, Kansas, United States

and more 30 locations

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Phase 2

Completed

Conditions: Pancreatic Cancer
Cholangiocarcinoma
Colon Cancer
Metastatic Colon Carcinoma
Liver Metastasis

Interventions: Drug: MVT-5873
Procedure: pancreatectomy or hepatectomy

First Posted Date: 2019-01-14

Last Posted Date: 2023-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03801915

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1

Active, not recruiting

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma
Locally Recurrent Lung Non-Small Cell Carcinoma
Unresectable Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8

Interventions: Radiation: Accelerated Hypofractionated Radiation Therapy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Durvalumab
Procedure: Magnetic Resonance Imaging of the Brain with and without Contrast
Biological: Monalizumab
Biological: Oleclumab
Radiation: Radiation Therapy

First Posted Date: 2019-01-14

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT03801902

Locations: 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 53 locations

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Refractory Multiple Myeloma
Recurrent Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Telaglenastat Hydrochloride

First Posted Date: 2019-01-10

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT03798678

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 2 locations

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Phase 2

Withdrawn

Conditions: Erdheim-Chester Disease

Interventions: Drug: Dabrafenib Mesylate
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Trametinib Dimethyl Sulfoxide

First Posted Date: 2019-01-07

Last Posted Date: 2021-03-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03794297

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy